在中国的肺炎球菌疫苗
Shanshan Wang1, Bin Li1, Qiong Chen1
1Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Research Units of Innovative Vaccine Quality Evaluation and Standardization, Chinese Academy of Medical Sciences, National Institutes of Food and Drug Control, Beijing, People's Republic of China.
Human vaccines & immunotherapeutics
|January 30, 2025
概括
侵入性肺炎球菌病 (IPD) 在中国构成重大威胁. 这份审查审查了IPD,可用的疫苗,如PPV23和PCV13,以及更好的控制和监测策略.
科学领域:
- 公共卫生 公共卫生
- 疫苗学 疫苗学 疫苗学
- 微生物学 微生物学
背景情况:
- 侵入性肺炎球菌病 (IPD) 是中国的主要疾病和死亡原因.
- 肺炎球菌疫苗对于预防IPD至关重要,PPV23和PCV13在国内可用.
研究的目的:
- 审查中国IPD目前的情况.
- 评估肺炎球菌疫苗的状态及其质量控制.
- 确定IPD控制的挑战和未来方向.
主要方法:
- 关于IPD流行病学的文献综述.
- 分析中国现有的肺炎球菌疫苗数据.
- 讨论质量控制措施和疾病负担.
主要成果:
- 在中国,IPD仍然是一个重大的公共卫生问题.
- 建立了PPV23和PCV13疫苗的国内生产.
- 需要考虑非疫苗血清型引起的IPD的可能性.
结论:
- 有效的IPD控制需要持续评估疾病负担.
- 监测疫苗的有效性对于公共卫生战略至关重要.
- 解决疫苗接种和质量控制方面的挑战对于减少IPD至关重要.
相关概念视频
Pneumonia III: Complications and Assessment
151
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
151
Viral Recombination
23.2K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.2K
Pneumonia I: Introduction
205
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
205
Pneumonia IV: Management
296
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
296
Vaccinations
43.9K
Overview
43.9K
Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K


